Payment overview · 2025
General Payments
$1,291.44
50 reported records · 25 companies
Healthcare provider profile · identity verified
Callie Davidson, NURSE PRACTITIONER
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PUEBLO, CO · NPI 1982289625
Verified facts
What the public records show
CMS Open Payments records show Callie Davidson, NURSE PRACTITIONER received $1,291.44 in general payments during 2025 across 50 reported records.
Novo Nordisk Inc accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Belbuca by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $264.12 | 20.4% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $150.90 | 11.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $149.44 | 11.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $123.34 | 9.6% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.44 | 3.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $47.74 | 3.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.49 | 3.4% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $41.35 | 3.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.31 | 3.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.69 | 3.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.10 | 3.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.32 | 2.4% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $30.64 | 2.4% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $29.11 | 2.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $23.15 | 1.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.51 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.23 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.28 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.45 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.90 | 1.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.82 | 1.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.79 | 1.3% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.08 | 1.2% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.87 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.37 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,291.44 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $150.90 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $143.53 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $124.41 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.00 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $82.08 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.96 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.96 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.38 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $47.74 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $41.35 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.31 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.69 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $40.10 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.10 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $31.32 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $29.11 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.03 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 113 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
113 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 398 | 102 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 281 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 240 | 46 |
| Pregabalin | Pregabalin | 181 | 33 |
| Belbuca | Buprenorphine Hcl | 113 | 27 |
| Gabapentin | Gabapentin | 112 | 37 |
| Buprenorphine | Buprenorphine | 109 | 39 |
| Morphine Sulfate Er | Morphine Sulfate | 71 | 16 |
| Atorvastatin Calcium | Atorvastatin Calcium | 70 | 33 |
| Baclofen | Baclofen | 70 | 30 |
| Tramadol Hcl | Tramadol Hcl | 67 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 20 |
| Hydromorphone Hcl | Hydromorphone Hcl | 59 | suppressed |
| Xtampza Er | Oxycodone Myristate | 53 | 11 |
| Ibuprofen | Ibuprofen | 45 | 20 |
| Lisinopril | Lisinopril | 44 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 17 |
| Lidocaine | Lidocaine | 43 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 14 |
| Celecoxib | Celecoxib | 41 | 11 |
| Tramadol Hcl Er | Tramadol Hcl | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 35 | 12 |
| Trazodone Hcl | Trazodone Hcl | 35 | 11 |
| Methocarbamol | Methocarbamol | 31 | 14 |
| Ondansetron Odt | Ondansetron | 27 | 22 |
| Meloxicam | Meloxicam | 26 | suppressed |
| Metformin Hcl | Metformin Hcl | 26 | 13 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Omeprazole | Omeprazole | 23 | 11 |
| Ozempic | Semaglutide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 11 |
| Losartan Potassium | Losartan Potassium | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | 12 |
| Jardiance | Empagliflozin | 15 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,291.44 · 50 records | Novo Nordisk Inc | ABRYSVO, AUSTEDO XR, Belbuca, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FANAPT, Flexitouch Plus, INGREZZA, JOURNAVX, Kerendia, Korlym, MOUNJARO, NEXPLANON, NURTEC ODT, Nimbl, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, Rystiggo, Symbravo, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZERBAXA, ZTLido | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error